Canada Spends Logo

Explore our Budget 2026 analysis

Grant: DRA: Canada Impact+ Research Training Awards - Doctoral

University of Toronto

$120,000.00

Lipid Nanoparticle-Based mRNA Therapeutics for Treating Neurodegenerative Diseases

FY 2025-26

Summary
"Neurodegenerative diseases slowly damage the brain and affect millions of people worldwide. These conditions have no effective treatments and often lead to loss of memory, movement, and independence. My research aims to develop new therapies by delivering biological “instruction manuals,” called mRNA, directly to the brain. Our lab has created a new delivery system using tiny fat-based particles known as lipid nanoparticles. Our version, termed P3B, was shown to efficiently carry mRNA into brain cells. In our studies, P3B performed better and showed improved safety compared to current industry-standard drug delivery systems. Goal 1: Fixing genetic mutations that cause brain damage ALSP is a rare, fatal neurodegenerative disease that is caused by a single mutation in a person’s DNA. This mutation reduces the number of immune cells in the brain, leading to problems with movement and memory. Using P3B, we aim to deliver gene-editing tools that correct this mutation in animal models, allowing the brain to restore normal function. Goal 2: Protecting the brain from Alzheimer’s disease Alzheimer’s disease is the most common neurodegenerative disease and is influenced by many factors. Research in human genetics has identified several proteins that may protect the brain from damage. In this project, we will use P3B to deliver mRNA that instructs the brain to produce these protective proteins in animal models. We will test which proteins, alone or in combination, are most effective at slowing brain damage and memory loss. This project can lead to new treatments for both rare genetic brain diseases and Alzheimer’s disease. In addition, it could establish a flexible delivery platform that can be adapted to treat many brain disorders that currently have no cure."
Program
DRA: Canada Impact+ Research Training Awards - Doctoral
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
568240
Name
You Justin
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Canada Impact+ Research Training Awards - Doctoral
Projecttitle
Lipid Nanoparticle-Based mRNA Therapeutics for Treating Neurodegenerative Diseases
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$120,000
Cihrequipment2
$0
Programname2
DRA: Canada Impact+ Research Training Awards - Doctoral
Keyworddelim
Alzheimer’S Disease; Lipid Nanoparticles; Mrna Therapy; Neurodegenerative Diseases; Rare Genetic Disease
Abstract
"Neurodegenerative diseases slowly damage the brain and affect millions of people worldwide. These conditions have no effective treatments and often lead to loss of memory, movement, and independence. My research aims to develop new therapies by delivering biological “instruction manuals,” called mRNA, directly to the brain. Our lab has created a new delivery system using tiny fat-based particles known as lipid nanoparticles. Our version, termed P3B, was shown to efficiently carry mRNA into brain cells. In our studies, P3B performed better and showed improved safety compared to current industry-standard drug delivery systems. Goal 1: Fixing genetic mutations that cause brain damage ALSP is a rare, fatal neurodegenerative disease that is caused by a single mutation in a person’s DNA. This mutation reduces the number of immune cells in the brain, leading to problems with movement and memory. Using P3B, we aim to deliver gene-editing tools that correct this mutation in animal models, allowing the brain to restore normal function. Goal 2: Protecting the brain from Alzheimer’s disease Alzheimer’s disease is the most common neurodegenerative disease and is influenced by many factors. Research in human genetics has identified several proteins that may protect the brain from damage. In this project, we will use P3B to deliver mRNA that instructs the brain to produce these protective proteins in animal models. We will test which proteins, alone or in combination, are most effective at slowing brain damage and memory loss. This project can lead to new treatments for both rare genetic brain diseases and Alzheimer’s disease. In addition, it could establish a flexible delivery platform that can be adapted to treat many brain disorders that currently have no cure."
Competitiondate
202603
Approvedterm2
3 yrs 0 mth
Pinamesdelim
You, Justin
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $120,000~ $0~